3-Hydroxyolean-12-en-27-oic Acids Inhibit RANKL-Induced Osteoclastogenesis in Vitro and Inflammation-Induced Bone Loss in Vivo

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 Jul 29

PMID 32718089

Citations 7

Authors

Wonyoung Seo

Suhyun Lee

Phuong Thao Tran

Thi Quynh-Mai Ngo

Okwha Kim

Thanh Huong Le

Nguyen Hai Dang

Cheol Hwangbo

Byung Sun Min

Jeong-Hyung Lee

Affiliations

Soon will be listed here.

Abstract

Olean-12-en-27-oic acids possess a variety of pharmacological effects. However, their effects and underlying mechanisms on osteoclastogenesis remain unclear. This study aimed to investigate the anti-osteoclastogenic effects of five olean-12-en-27-oic acid derivatives including 3α,23-isopropylidenedioxyolean-12-en-27-oic acid (AR-1), 3-oxoolean-12-en-27-oic acid (AR-2), 3α-hydroxyolean-12-en-27-oic acid (AR-3), 23-hydroxy-3-oxoolean-12-en-27-oic acid (AR-4), and aceriphyllic acid A (AR-5). Among the five olean-12-en-27-oic acid derivatives, 3-hydroxyolean-12-en-27-oic acid derivatives, AR-3 and AR-5, significantly inhibited receptor activator of nuclear factor-κB ligand (RANKL)-induced mature osteoclast formation by reducing the number of tartrate-resistant acid phosphatase (TRAP)-positive osteoclasts, F-actin ring formation, and mineral resorption activity. AR-3 and AR-5 decreased RANKL-induced expression levels of osteoclast-specific marker genes such as c-Src, TRAP, and cathepsin K (CtsK) as well as c-Fos and nuclear factor of activated T cells cytoplasmic 1 (NFATc1). Mice treated with either AR-3 or AR-5 showed significant protection of the mice from lipopolysaccharide (LPS)-induced bone destruction and osteoclast formation. In particular, AR-5 suppressed RANKL-induced phosphorylation of JNK and ERK mitogen-activated protein kinases (MAPKs). The results suggest that AR-3 and AR-5 attenuate osteoclast formation in vitro and in vivo by suppressing RANKL-mediated MAPKs and NFATc1 signaling pathways and could potentially be lead compounds for the prevention or treatment of osteolytic bone diseases.

Citing Articles

3D-Printed Biomimetic Hydroxyapatite Composite Scaffold Loaded with Curculigoside for Rat Cranial Defect Repair.

Weng Y, Yuan X, Fan S, Duan W, Tan Y, Zhou R ACS Omega. 2024; 9(24):26097-26111.

PMID: 38911726 PMC: 11190930. DOI: 10.1021/acsomega.4c01533.

Gallic acid inhibits osteoclastogenesis and prevents ovariectomy-induced bone loss.

Zhang P, Ye J, Dai J, Wang Y, Chen G, Hu J Front Endocrinol (Lausanne). 2023; 13:963237.

PMID: 36601012 PMC: 9807166. DOI: 10.3389/fendo.2022.963237.

Lipopolysaccharide-Induced Bone Loss in Rodent Models: A Systematic Review and Meta-Analysis.

Bott K, Feldman E, de Souza R, Comelli E, Klentrou P, Peters S J Bone Miner Res. 2022; 38(1):198-213.

PMID: 36401814 PMC: 10107812. DOI: 10.1002/jbmr.4740.

Parkin Inhibits RANKL-Induced Osteoclastogenesis and Ovariectomy-Induced Bone Loss.

Hou W, Chen M, Ye C, Chen E, Li W, Zhang W Biomolecules. 2022; 12(11).

PMID: 36358952 PMC: 9687699. DOI: 10.3390/biom12111602.

Reversing the imbalance in bone homeostasis via sustained release of SIRT-1 agonist to promote bone healing under osteoporotic condition.

Zhang W, Zhou X, Hou W, Chen E, Ye C, Chen M Bioact Mater. 2022; 19:429-443.

PMID: 35574058 PMC: 9079176. DOI: 10.1016/j.bioactmat.2022.04.017.

References

Boyle W, Simonet W, Lacey D . Osteoclast differentiation and activation. Nature. 2003; 423(6937):337-42. DOI: 10.1038/nature01658. View

Kim J, Cheon Y, Oh H, Rho M, Erkhembaatar M, Kim M . Oleanolic acid acetate inhibits osteoclast differentiation by downregulating PLCγ2-Ca(2+)-NFATc1 signaling, and suppresses bone loss in mice. Bone. 2013; 60:104-11. DOI: 10.1016/j.bone.2013.12.013. View

Kikuta J, Ishii M . Osteoclast migration, differentiation and function: novel therapeutic targets for rheumatic diseases. Rheumatology (Oxford). 2012; 52(2):226-34. DOI: 10.1093/rheumatology/kes259. View

Lee I, Yoo J, Na M, Min B, Lee J, Yun B . Cytotoxicity of triterpenes isolated from Aceriphyllum rossii. Chem Pharm Bull (Tokyo). 2007; 55(9):1376-8. DOI: 10.1248/cpb.55.1376. View

Teitelbaum S, Ross F . Genetic regulation of osteoclast development and function. Nat Rev Genet. 2003; 4(8):638-49. DOI: 10.1038/nrg1122. View

Yu W, Chen J, Xiong Y, Pixley F, Yeung Y, Stanley E . Macrophage proliferation is regulated through CSF-1 receptor tyrosines 544, 559, and 807. J Biol Chem. 2012; 287(17):13694-704. PMC: 3340183. DOI: 10.1074/jbc.M112.355610. View

Zheng C, Oh H, Kim W . Potent anticariogenic activity of Aceriphyllum rossii and its components, aceriphyllic acid A and 3-oxoolean-12-en-27-oic acid. J Food Sci. 2010; 75(2):M78-82. DOI: 10.1111/j.1750-3841.2009.01476.x. View

Sheng H, Sun H . Synthesis, biology and clinical significance of pentacyclic triterpenes: a multi-target approach to prevention and treatment of metabolic and vascular diseases. Nat Prod Rep. 2011; 28(3):543-93. DOI: 10.1039/c0np00059k. View

Han J, Kim H, Park Y, Lee Y, Lee K, Kwon B . Aceriphyllic acid A, A new ACAT inhibitory triterpenoid, from Aceriphyllum rossii. Planta Med. 2002; 68(6):558-61. DOI: 10.1055/s-2002-32565. View

10.

Newman D, Cragg G . Natural Products as Sources of New Drugs from 1981 to 2014. J Nat Prod. 2016; 79(3):629-61. DOI: 10.1021/acs.jnatprod.5b01055. View

11.

Lomaga M, Yeh W, Sarosi I, Duncan G, Furlonger C, Ho A . TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 1999; 13(8):1015-24. PMC: 316636. DOI: 10.1101/gad.13.8.1015. View

12.

Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H . Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002; 3(6):889-901. DOI: 10.1016/s1534-5807(02)00369-6. View

13.

Zhao D, Li X, Zhao Y, Qiao P, Tang D, Chen Y . Oleanolic acid exerts bone protective effects in ovariectomized mice by inhibiting osteoclastogenesis. J Pharmacol Sci. 2018; 137(1):76-85. DOI: 10.1016/j.jphs.2018.03.007. View

14.

Min B, Lee I, Chang M, Yoo J, Na M, Manh Hung T . Anticomplementary activity of triterpenoids from the whole plant of Aceriphyllum rossii against the classical pathway. Planta Med. 2008; 74(7):726-9. DOI: 10.1055/s-2008-1074534. View

15.

Xuan W, Feng X, Qian C, Peng L, Shi Y, Xu L . Osteoclast differentiation gene expression profiling reveals chemokine CCL4 mediates RANKL-induced osteoclast migration and invasion via PI3K pathway. Cell Biochem Funct. 2017; 35(3):171-177. DOI: 10.1002/cbf.3260. View

16.

Trang T, Cuong T, Manh Hung T, Kim J, Lee J, Woo M . Anti-inflammatory compounds from the aerial parts of Aceriphyllum rossii. Chem Pharm Bull (Tokyo). 2014; 62(2):185-90. DOI: 10.1248/cpb.c13-00664. View

17.

Takeshita S, Faccio R, Chappel J, Zheng L, Feng X, Weber J . c-Fms tyrosine 559 is a major mediator of M-CSF-induced proliferation of primary macrophages. J Biol Chem. 2007; 282(26):18980-90. DOI: 10.1074/jbc.M610938200. View

18.

Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C . Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways. J Bone Miner Res. 2010; 26(3):644-56. DOI: 10.1002/jbmr.242. View

19.

Seo J, Kim M, Han A, Kwon E, Kang M, Cho S . Oleanane-type triterpenoids of Aceriphyllum rossii and their diacylglycerol acyltransferase-inhibitory activity. Planta Med. 2015; 81(3):228-34. DOI: 10.1055/s-0034-1396242. View

20.

Corbo F, Brunetti G, Crupi P, Bortolotti S, Storlino G, Piacente L . Effects of Sweet Cherry Polyphenols on Enhanced Osteoclastogenesis Associated With Childhood Obesity. Front Immunol. 2019; 10:1001. PMC: 6509551. DOI: 10.3389/fimmu.2019.01001. View